Ultragenyx Pharmaceutical (RARE) Cash from Operations (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash from Operations data on file, last reported at 197000000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 18.67% year-over-year to 197000000.0 in Q1 2026; TTM through Mar 2026 was 497000000.0, a 27.67% decrease from a year earlier, with the FY2025 full-year figure at 466000000.0, down 12.56% from the prior year.
• Cash from Operations for Q1 2026 stood at 197000000.0, down from 99829000.0 in the prior quarter.
• Over the last five years, Cash from Operations for RARE reached as high as 66995000.0 in Q3 2024 and fell as low as 197000000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 113674411.76 across 5 years, with a median of 99829000.0 in 2025.
• Across the five-year window, Cash from Operations slumped 66.24% in 2022 and soared 43.16% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 90342000.0 in 2022, then grew by 6.91% to 84098000.0 in 2023, then climbed by 5.69% to 79315000.0 in 2024, then slipped by 25.86% to 99829000.0 in 2025, then tumbled by 97.34% to 197000000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 197000000.0 in Q1 2026, 99829000.0 in Q4 2025, and 91423000.0 in Q3 2025.